1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Summary of complications during the follow-up period
Adverse Events At Discharge (n = 52 cases) Ratio 3-Month Follow-Up (n = 43 cases) Ratio 12-Month Follow-Up (n = 36 cases) Ratio
Hemorrhagic 0 0.0% 1 2.3% 0 0.0%
Thromboembolic, symptomatic 1 1.9% 0 0.0% 1 2.8%
Thromboembolic, asymptomatic 3 5.7% 2 4.7% 1 2.8%
Total 4 7.6% 3 7.0% 2 5.6%

Adverse Events	At Discharge (n = 52 cases)	Ratio	3-Month Follow-Up (n = 43 cases)	Ratio	12-Month Follow-Up (n = 36 cases)	Ratio
Hemorrhagic	0	0.0%	1	2.3%	0	0.0%
Thromboembolic, symptomatic	1	1.9%	0	0.0%	1	2.8%
Thromboembolic, asymptomatic	3	5.7%	2	4.7%	1	2.8%
Total	4	7.6%	3	7.0%	2	5.6%